In 2021, Intellia Therapeutics dosed NTLA‐2002 to patients in a phase I/II clinical trial for hereditary angioedema (HAE), where NTLA‐2002 acts as a gene therapy that inactivates kallikrein B1 (KLKB1) and prevents HAE attacks. The gene discussed is KLKB1; the disease is hereditary angioedema.